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sent in Chronic Phase (CP) versus Accelerated Phase (AP) or
with acute leukemic blast crisis (BC) CML. For patients with
CP-CML prognosis is excellent when treated with TKIs alone
while for patients with AP- or BC-CML, the goal of therapy is
to get back into chronic phase CML and then proceed to an
allogeneic bone marrow transplant (allo-BMT). Even with
this intensiﬁed approach, patients with advanced CML his-
torically have had a poor prognosis with an OS ofw65% one
year after allo-BMT. In the pre-TKI era roughly 20% of patients
with CML would progress to blast crisis. This has declined to
w1% in the TKI era, but the overall survival of these patients
has not changed.
Methods: After obtaining IRB approval, we reviewed the
medical records of all patients evaluated for allo-BMT for
CML at our institution between January 1, 2010 and June 30,
2013. There were ﬁve children who presented with CML in
accelerated phase or blast crisis.
Results: Five patients developed advanced stage CML during
the observed period. Ages ranged from 12-18 years old at the
time of transplant (median age 13). The male:female ratio
was 4:1. 4/5 presented in lymphoid blast crisis and 1/5 in
accelerated phase. All patients were started on imatinib
though two required a second or third line TKI to achieve
stable phase prior to transplant. Prior to transplant, all
patients were in at least a morphologic and cytogenetic
remission; 3/5 also were in a molecular remission. 4/5 pa-
tients received a matched unrelated donor transplant; the
other underwent a matched sibling transplant. Conditioning
was TBI (1440 cGy) and Cyclophosphamide. GVHD prophy-
laxis was Cyclosporine and Methotrexate with Prednisone
added for unrelated donors per our institutional standard.
Median day of engraftment was + 24. 1/5 patients developed
stage 2-4 aGVHD and none developed grade 3-4 aGVHD.
TKI’s were restarted in all patients (median day 114) with a
goal of continuing until 2 years post transplant. One patient
developed joint pain and night sweats which resolved with
dose reduction, another myelosuppression which resolved
with TKI holiday and dose reduction. All patients are alive
and remain in molecular remission with undetectable BCR-
ABL transcript with an average duration of remission of 435
days [190-1347].
Discussion: The outcomes of children with CML presenting
in blast crisis in the era of TKIs has not been previously
documented. The use of TKI’s pre- and post-transplant may
lead to improved disease free survival for this group. Disease
control prior to SCT and close monitoring remain essential
for optimal outcome.268
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Background: Congenital hydrocephalus affects 0.3 to 1.5 per
1000 live births, is typically diagnosed in utero, and may
occur in isolation or as a result of a genetic or other
underlying cause. Current standard therapy involves ven-
triculoperitoneal shunt placement shortly after birth to
divert the ﬂow of cerebrospinal ﬂuid and decreaseintracranial pressure. However, survivors face the sequelae of
brain injury resulting from the prolonged hydrocephalic
state in utero. Umbilical cord blood (CB) has been shown to
lessen the clinical and radiographic impact of hypoxic brain
injury and stroke in animal models. Based on this data, we
began to treat infants with congenital hydrocephalus with
multiple autologous CB infusions during the ﬁrst 1-2 years of
life to determine the safety and feasibility of the procedure.
Methods: Parents of children diagnosed with congenital
hydrocephalus in utero elected to store their child’s CB in a
private or public bank as a directed donor. CB units were
deemed eligible based on results of, cell count, sterility,
potency and infectious disease screening. On the day of
infusion, CB units were thawed and washed in dextran-al-
bumin and infused via peripheral IV in the outpatient clinic
after premedicationwith acetaminophen, diphenhydramine,
and methylprednisolone. When possible, CB units were
fractionated to allow for multiple doses over time.
Results: Since 2006, 70 patients with congenital hydro-
cephalus have been treated with 129 autologous CB in-
fusions. Most babies received repeated doses, for a total of 2
(N¼24), 3 (N¼12), or 4 (N¼4) infusions. Median age at the
ﬁrst infusion was 2 months (range 6 days e 4 years). Median
cell doses per infusion were TNC 2.0x107/kg (range 0.1-
13.3x107/kg) and CD34 count 0.7 x105/kg (range 0.04-
6.4x105/kg). The infusions were well tolerated, with no acute
or chronic adverse events. Anecdotally, parents report that
their children are making developmental gains after autol-
ogous CB infusion.
Conclusions: Autologous CB infusion is safe and feasible in
babies with congenital hydrocephalus. Since the diagnosis is
typically made in utero, there is sufﬁcient time to plan for CB
collection prior to delivery. As the patients are so young and
small at the time of treatment, a single CB unit can often be
fractionated to permit a multiple dosing strategy. While in-
fants make developmental progress after the infusions,
additional studies are necessary to determine if these gains
are related to the CB treatment.269
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In Asia, where the chance of ﬁnding a HLA 10/10 allele
matched adult donor in a short time is low; stem cell donors
including mismatched unrelated cord blood and family
haploidentical stem cell donors are feasible alternatives.
Between Jan 2007 and Sep 2013, a total of 14 haploidentical
stem cell transplants (SCT) in 13 patients were performed in
our Pediatric SCT Program. Of the 9 boys and 4 girls, SCT was
performed in 2 for non-malignant diseases (1 Hurler’s, 1
Hepatitis Associated Severe Aplastic Anemia) and 11 for very
high risks malignancies (4 ALL, 3 AML, 3 Lymphoma, 1 MDS/
RAEB). Preparative regimen was tailored to pre-morbid sta-
tus and was reduced intensity (N¼6) which included single
TBI 2 Gy  Fludarabine/ Cyclophosphamide or full prepara-
tion (N¼8) with Fludarabine, Thiotepa, Melphalan, ATG
(Thymoglobulin), Rituximab and TLI 6-8Gy or TBI 6Gy.
Table
SCT Diagnosis Status at SCT Preparative regimen TBI/ TLI
dose
Outcome Survival at last follow-up
(Oct 13)
1 Hurler’s Advanced disease Full prep/CD34 selected
PBSCT
- Engrafted D+10; secondary
graft failure; auto-reconstituted
Alive at 2 years/ lost to
follow-up
2 Hepatitis
Associated Aplastic
Anemia
Post liver transplant/
prolonged aplasia
Reduced intensity/
T- deplete BMT
- Engrafted D+14, secondary
graft failure; auto-reconstituted
Alive at 4 years/ lost to
follow-up
3 Hodgkin
Lymphoma
3rd relapse Reduced
intensity/ T replete BMT
TBI 2Gy Engrafted D+13; remission
D+60; relapsed D+98
Died of disease D+192
4 Therapy- Related
AML
1st remission Reduced intensity/
T- replete BMT
TBI 2Gy Engrafted D+14; remission
D+21; relapsed D+61
Died of disease 0+164
5 Therapy- Related
AML
Progressive disease/ NK
cell therapy/ 2nd SCT
NK conditioning/
T-deplete PBSCT
TBI 2Gy Engrafted D+9, remission D+2l,
MRD relapsed D+176/ DLI & NK
cell therapy
Alive, D+379
6 B Lineage ALL 2nd remission Full prep/T- deplete
PBSCT
TLI 8Gy Engrafted D+10; remission
since 0+21
Alive, D+365
7 B Lineage ALL 2nd remission Full prep/T- deplete
PBSCT
TLI 8Gy Engrafted D+10; remission
since D+21
Alive, D+365
8 Anaplastic Large
Cell Lymphoma
Progressive disease Reduced intensity/
T- deplete PBSCT
- Engrafted D+1; remission since
D+7, severe GVHD
Alive, D+200
9 Second AML Progressive disease/ NK
cell therapy/ 3rd SCT
Full prep/T- deplete
(TCRab) PBSCT
TLI 6Gy Engrafted D+10; remission
0+21: relapsed 0+60
Died of regimen-related
tonicity (encephalopathy)/
disease D+90
10 Burkitt’s lymphoma Progressive disease/ NK
cell therapy
Full prep/T- deplete
(TCRab) PBSCT
TBI 6Gy Engrafted D+8; remission D+21;
relapsed D+31/ DLI therapy
Alive, D+97
11 Early T Cell All 1st remission Full prep/T deplete
(TCRab) PESCT
TBI 6Gy Engrafted D+8; remission Died of regimen- related
tonicity (hepatic failure)
D+21
12 MDS/RAEB Evolving disease Full prep/T- deplete
(TCRab) PBSCT
TLI 6Gy Engrafted transiently; graft
failure
Alive, D+41, in 2nd SCT
13 t lineage AH 2nd remission Full prep/T deplete
(TTCRab) PBSCT
TLI 6Gy Engrafted D+10, remission
D+21
Alive, D+34
14 MDS/RAEB Graft failure/ 2nd SCT Redund intensity/
T- replete BMT
TBI 2Gy Awaiting engraftment Alive, D+13 of 2nd SCT
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(N¼4) depletion was performed in 10 SCT and CD34 positive
selection in 1. The other 3 patients received T-replete SCT
with post-transplant cyclophosphamide as per Hopkins
protocol. For the 11 T-deplete SCT, the median CD34 (x106/
kg) was 8.8 (range, 3.4-24.2) and CD3 (x104/kg) was 5 (range,
0-11). For the 3 T-replete SCT, the median TNC (x108/kg) was
2.9 (range, 2.9-4.2); CD34 (x106/kg) was 3.9 (range, 1.4-5.5)
and CD3 (x108/kg) was 0.4 (range, 0.2-2.9). For the 2 patients
with non-malignant diseases, both suffered secondary graft
failure, auto-reconstituted and survived. For the 11 patients
with high risk cancers; 6 had progressive disease at time of
SCT; 4 are surviving (1 in remission, 3 with disease) and 2
died of disease. Of the 5 patients entering SCT in remission; 3
are alive and in remission; 1 died of disease and another of
regimen-related toxicity. In 11 T-deplete SCT, viral reac-
tivations of CMV, Adenovirus, EBV, BK virus occurred in 8, 3,
3, and 2 patients, respectively. The preliminary experience of
haploidentical SCT in our small cohort of patients is
encouraging with no infective mortality and good engraft-
ment rates even for patients entering SCTwith bulky disease.
‘Graft versus leukemia/ lymphoma’ effects are evident and
may be exploited further through adoptive cell therapy in
post-transplant settings to achieve more durable remissions.270
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Standard conditioning regimes for myeloid malignancies
are TBI or Busulfan-based with Cyclophosphamide. The
reported event-free survival (EFS) is 40-60% and trans-
plant-related mortality (TRM) of 4-30%. We designed a
regime of Fludarabine, Busulfan and Melphalan (FluBuMel)
in an attempt to increase the survival rate without
increased TRM.
Methods: Retrospective review of pediatric patients with
myeloid malignancies who underwent HSCT at our institu-
tion from September 2005 to September 2010.
Results: There were 19 patients who underwent HSCT in the
time period. Median age is 5 (range, 1-20) years. There were
15 patients in CR1, 2 patients in CR2 and 2 patients not in CR.
Patients received Fludarabine (120mg/m2) + Busulfan,
weight-based dosing + Melphalan 140mg/m2 (15 patients)
decreased to 70mg/m2 (3 patients), and 1 infant with weight
adjusted dose with Cyclosporine + ATG + MTX as GVHD
prophylaxis. Average length of stay fromDay 0 to discharge is
28 (range, 17-51) days. All patients achieved neutrophil
recovery at median 14 (range, 10-46) days. All patients ach-
ieved > 95% chimerism (D+21) and 100% (D+100). Regimen-
related toxicities were CTC grade 2-3 mucositis (89%),
seizures (10%) and sinusoidal obstruction syndrome (SOS)
(15%). Decreasing the Melphalan dose did not decrease the
occurrence of mucositis and SOS in the 3 patients. Busulfan
pharmacokinetics was not measured; all patients received
phenytoin prophylaxis at therapeutic levels. The 100-day
TRM is 0%. Overall, 47% had grade 1-2 aGVHD, 21 % grade 3-4
aGVHD and 76% had cGVHD. The 2-year overall survival (OS)
